loading...| Preferred Name |
levodopa |
|
| Synonyms |
(--)-2amino-3-)3,4-dihydroxyphenyl)propanoic acid |
|
| Definitions |
An amino acid precursor of dopamine with antiparkinsonian properties. Levodopa is a prodrug that is converted to dopamine by DOPA decarboxylase and can cross the blood-brain barrier. When in the brain, levodopa is decarboxylated to dopamine and stimulates the dopaminergic receptors, thereby compensating for the depleted supply of endogenous dopamine seen in Parkinson's disease. To assure that adequate concentrations of levodopa reach the central nervous system, it is administered with carbidopa, a decarboxylase inhibitor that does not cross the blood-brain barrier, thereby diminishing the decarboxylation and inactivation of levodopa in peripheral tissues and increasing the delivery of dopamine to the CNS. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C611" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C611" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000042622 |
|
| altLabel |
(--)-2amino-3-)3,4-dihydroxyphenyl)propanoic acid Laradopa Deadopa beta-(3,4-dihydroxyphenyl)-L-alanine Doprin Dopaston Parda Dopaidan Doparl 3-hydroxy-L-tyrosine Doparkine Dopaflex Veldopa Eldopar Maipedopa Dopar Eurodopa Dopasol Levopa Dopal Dopalina Bendopa Ledopa L-dopa Eldopal Eldopatec (--)-3-(3,4-dihydroxyphenyl)-L-alanine Dopastral Larodopa Cidandopa |
|
| cui |
C1517860 C1449995 C1517849 C1517857 C1517851 C1517864 C1517859 C1517861 C1517856 C1517863 C1517846 C0023570 C1517854 C1517847 C1517855 C0700880 C1517850 C1517845 C0699991 C1517858 C1517862 C1517853 C0720022 C1517848 C1517865 C1517852 |
|
| Date last modified |
2006-12-27 |
|
| definition |
An amino acid precursor of dopamine with antiparkinsonian properties. Levodopa is a prodrug that is converted to dopamine by DOPA decarboxylase and can cross the blood-brain barrier. When in the brain, levodopa is decarboxylated to dopamine and stimulates the dopaminergic receptors, thereby compensating for the depleted supply of endogenous dopamine seen in Parkinson's disease. To assure that adequate concentrations of levodopa reach the central nervous system, it is administered with carbidopa, a decarboxylase inhibitor that does not cross the blood-brain barrier, thereby diminishing the decarboxylation and inactivation of levodopa in peripheral tissues and increasing the delivery of dopamine to the CNS. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C611" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C611" NCI Thesaurus) |
|
| Legacy PDQ ID |
6342 |
|
| LT |
TRD |
|
| NCI ID |
C611 |
|
| notation |
CDR0000042622 |
|
| NSC Code |
118381 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
levodopa |
|
| tui |
T116 T123 T121 |